Investigational drug · Phase 2
QLS12010
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA).
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "QLS12010"
First trial start
2026
Mar 5, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS12010", any sponsor or status.
Conditions studied
As listed on its trial records.
- Adults With Moderate-to-severe Hidradenitis Suppurativa
- Moderate-to-severe Atopic Dermatitis
- Rheumatoid Arthritis (RA)
Approved drugs for the same conditions: Rheumatoid arthritis · Atopic dermatitis (eczema) · Hidradenitis suppurativa · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS12010" as an intervention, largest first.
- QLS12010 in Participants With Moderate-to-severe Rheumatoid ArthritisPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07377773 · 180 participants (planned) · Start Mar 5, 2026 · Primary completion Mar 5, 2028
Drug: QLS12010; placebo · For: Rheumatoid Arthritis (RA)
- A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic DermatitisPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07344051 · 160 participants (planned) · Start Apr 5, 2026 · Primary completion Sep 2027
Drug: QLS12010; Placebo · For: Moderate-to-severe Atopic Dermatitis
- QLS12010 Capsules in Adults With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07417917 · 102 participants (planned) · Start Apr 1, 2026 · Primary completion Jun 1, 2027
Drug: QLS12010; Placebo · For: Adults With Moderate-to-severe Hidradenitis Suppurativa
- A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis PatientsPivotal-lookingRecruiting
Shanghai Qilu Pharmaceutical Research and Development Center LTDIndustry
NCT06946641 · 102 participants (planned) · Start Mar 31, 2025 · Primary completion Dec 2025
Drug: QLS12010; Placebo · For: Atopic Dermatitis; Hidradenitis Suppurativa (HS); Rheumatoid Arthritis (RA)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.